Analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.
Several other research firms also recently issued reports on MBRX. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Moleculin Biotech in a report on Monday. Maxim Group cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.
Get Our Latest Stock Analysis on MBRX
Moleculin Biotech Price Performance
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Articles
- Five stocks we like better than Moleculin Biotech
- There Are Different Types of Stock To Invest In
- GitLab: Get In While It’s Down—Big Rebound Ahead
- What is a Secondary Public Offering? What Investors Need to Know
- Tesla Stock: Finding a Bottom May Take Time
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
